Erlotinib Completed Phase 1 / 2 Trials for Brain and Central Nervous System Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00509431Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma